CMS NCD 22 Update: Electric Nerve Stimulation for Motor Function Disorders — What Billing Teams Need to Know

The Centers for Medicare & Medicaid Services (CMS) has issued a modification to National Coverage Determination (NCD) 22, which governs coverage of electric nerve stimulation for the treatment of motor function disorders. This policy update, effective March 12, 2026, reinforces CMS's longstanding non-coverage position for electric nerve stimulation when used to treat conditions like multiple sclerosis. If your practice or facility bills Medicare for any neurostimulation services, this policy warrants a close look before claims go out the door.

What CMS NCD 22 Covers — and What It Doesn't

CMS has a well-established framework distinguishing between covered and non-covered uses of electric nerve stimulation. The core issue with NCD 22 is the indication: motor function disorders.

Electric nerve stimulation has been an accepted tool for managing chronic intractable pain for years. That's a separate clinical application with its own coverage rules (see NCD §160.7, the NCD on Electrical Nerve Stimulators). The moment the clinical indication shifts from pain management to motor function improvement — in conditions such as multiple sclerosis — Medicare's coverage position changes entirely.

Under NCD 22, CMS explicitly states that electric nerve stimulation used to treat motor function disorders cannot be considered reasonable and necessary. That's the standard CMS uses to determine Medicare reimbursement eligibility, and failing to meet it means no payment — full stop.

The Medical Necessity Problem: Why CMS Won't Reimburse This Service

The "reasonable and necessary" standard is foundational to Medicare billing. When CMS invokes it as a reason for non-coverage, it signals that the clinical evidence simply hasn't met the bar required for national coverage.

According to the policy language, while the use of electric nerve stimulation for motor function disorders is described as a "recent innovation," the medical effectiveness of such therapy has not been verified by scientifically controlled studies. That lack of controlled evidence is the disqualifying factor.

This is essentially an experimental or investigational designation in practical terms — CMS is saying the evidence base doesn't support covering this treatment at the national level. Providers should not expect to overcome this through local coverage determinations without significant new clinical evidence, and they certainly shouldn't assume an Advance Beneficiary Notice (ABN) will make a claim payable. Non-covered services that fall under a national non-coverage determination are typically not billable to Medicare regardless of ABN status, though the ABN process may still be relevant for patient financial responsibility documentation depending on the scenario.

Where Deep Brain Stimulation Fits In — A Critical Distinction

One of the most important cross-references in NCD 22 points to §160.24, which covers deep brain stimulation (DBS) for essential tremor and Parkinson's disease.

This distinction matters enormously for neurology and neurosurgery billing teams. Parkinson's disease and essential tremor do involve motor dysfunction, but DBS for those specific conditions has its own separate NCD with its own coverage criteria. That coverage exists because the clinical evidence for DBS in those indications has met CMS's threshold.

If your team is billing for DBS related to Parkinson's disease or essential tremor, you should not be looking at NCD 22 — you should be working under §160.24 and its associated requirements. Conflating these two policies is a claim denial risk that's easy to avoid with proper routing.

Affected Codes

The policy does not list specific CPT or HCPCS codes. NCD 22 applies broadly to electric nerve stimulators and related implantation services when billed under a motor function disorder indication. For code-level guidance on electrical nerve stimulators more broadly, cross-reference NCD §160.7.

Covered Codes

No codes are designated as covered under NCD 22 for the motor function disorder indication.

Non-Covered Services Under NCD 22

Note: No specific CPT or HCPCS codes are enumerated in the policy document. Billing teams should review NCD §160.7 for code-level detail on electrical nerve stimulators and §160.24 for DBS coverage codes under Parkinson's disease and essential tremor.

What Your Billing Team Should Do